What is Eli Lilly's market share in GLP-1?

Eli Lilly captured approximately 60% of the GLP-1 market in Q1 2026.

How much did Mounjaro revenue grow in Q1 2026?

Mounjaro revenue surged 125% year-over-year in Q1 2026.

Why are analysts talking about a Mounjaro economy instead of Ozempic?

Due to Lilly's 60% GLP-1 market share and Mounjaro's strong growth, analysts believe Mounjaro is now the primary market driver.

Mounjaro is an Eli Lilly drug used for type 2 diabetes and obesity, belonging to the GLP-1 class.

Eli Lilly Captures 60% of GLP-1 Market as Mounjaro Revenue Surges 125%

Eli Lilly's Q1 2026 earnings show it now controls 60% of the GLP-1 market, driven by a 125% surge in Mounjaro revenue, leading Morning Brew Daily hosts to suggest replacing 'Ozempic economy' with 'Mounjaro economy'.

Eli Lilly (NYSE:LLY) reported Q1 2026 earnings that underscore its dominance in the GLP-1 drug market, capturing a 60% share as Mounjaro revenue soared 125% year-over-year. The strong performance prompted Morning Brew Daily hosts to argue that the "Ozempic economy" should be rebranded as the "Mounjaro economy."

Key Financial Results

Metric	Value
GLP-1 Market Share	60%
Mounjaro Revenue Growth (YoY)	125%
Total Revenue (Q1 2026)	Not yet disclosed
Net Income	Not yet disclosed
EPS	Not yet disclosed

Highlights from the Report

Lilly attributed the growth to robust demand for Mounjaro, used for type 2 diabetes and obesity, and expanded manufacturing capacity. The company emphasized its leadership in the expanding GLP-1 market.

Future Guidance

No specific guidance for the next quarter was provided, but analysts expect continued growth driven by increased adoption and potential label expansions.

Stock Impact

The stock reaction was not detailed, but the strong results are likely to support LLY shares, especially given its competitive edge over Novo Nordisk's Ozempic.

What This Means for Investors

Lilly's Q1 results highlight its competitive strength in the GLP-1 space, supporting long-term growth prospects. Investors should monitor competitive dynamics, capacity expansions, and regulatory developments.